Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04413201
Recruitment Status : Recruiting
First Posted : June 2, 2020
Last Update Posted : September 30, 2020
Sponsor:
Collaborator:
Boehringer Ingelheim
Information provided by (Responsible Party):
Michael Hopp, Johannes Gutenberg University Mainz

Brief Summary:
This randomized, open label Phase IV trial will be performed in patients with a diagnosis of advanced NSCLC (non-squamous cell histology), harboring EGFR mutation positive but T790M Mutation negative, who have no previous chemotherapy for metastatic NSCLC. Neoadjuvant or adjuvant systemic treatments had to be finished at least (≥) 6 months before study inclusion. In conclusion, this study is investigating the important clinical question whether tumor growth and long term overall survival for a patient is better controlled in a specific treatment sequence of different EGFR-inhibitors. Patients will be treated with registered compounds according to their label in both treatment arms. Thus, all patients will get an effective treatment regimen and patients who progressed on afatinib, and who developed a T790M mutation will be treated subsequently with osimertinib. Those who progressed under osimertinib or under afatinib without T790M mutation will be treated according to the current treatment guidelines with Investigator´s choice of active therapy (ICT) including but not limited to platin doublet chemotherapy.

Condition or disease Intervention/treatment Phase
Non-squamous NSCLC Drug: Afatinib Drug: Osimertinib Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 126 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: AFAMOSI: Prospective, Randomized, Multicenter Phase IV Study to Evaluate the Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Non-squamous NSCLC in the First-line Setting
Actual Study Start Date : September 11, 2020
Estimated Primary Completion Date : June 30, 2024
Estimated Study Completion Date : June 30, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Afatinib
Afatinib followed by osimertinib or ICT depending on T790M status
Drug: Afatinib
Afatinib followed by osimertinib or ICT
Other Name: Osimertinib

Drug: Osimertinib
Osimertinib followed by ICT

Active Comparator: Osimertinib
Osimertinib followed by ICT
Drug: Osimertinib
Osimertinib followed by ICT




Primary Outcome Measures :
  1. Time to EGFR-TKI failure within 24 months for afatinib followed by osimertinib in T790Mpositive group vs osimertinib [ Time Frame: 24 months ]
    The main objective is to investigate whether the time to EGFR-TKI failure at 24 months is better for the treatment sequence of afatinib followed by osimertinib in the T790M positive group compared to osimertinib.


Secondary Outcome Measures :
  1. Time to EGFR-TKI failure (afatinib versus osimertinib) [ Time Frame: 24 months ]
    Time from randomization until ICT is indicated

  2. Progression-free survival (PFS: afatinib followed by osimertinib or ICT vs osimertinib followed by ICT) [ Time Frame: 24 months ]
    Time from randomization until disease progression according to RECIST or death

  3. Overall Survival (OS) [ Time Frame: 24 months ]
    Survival Status

  4. Response Rate (RR) [ Time Frame: 12 months ]
    CR+PR according to RECIST

  5. Response Rate (RR) [ Time Frame: 24 months ]
    CR+PR according to RECIST

  6. Disease Control Rate (DCR) [ Time Frame: 12 months ]
    CR+PR+SD according to RECIST

  7. Disease Control Rate (DCR) [ Time Frame: 24 months ]
    CR+PR+SD according to RECIST

  8. Adverse Events [ Time Frame: 24 months ]
    Adverse Events as assessed by intensity of the of the adverse events and the causal relation to trial medication Intensity/Severity: investigator will use the following definitions of severity in accordance with National Cancer Institute common terminology criteria for adverse events, CTCAE, version 5.0; assessment of the relationship of an adverse event to the administration of study drug is a clinical decision by the investigator Institute common terminology criteria for adverse events, CTCAE, version 5.0

  9. Symptom control assessed by patient-reported quality of life (QoL): EQ-5D [ Time Frame: 24 months ]
    patient-reported quality of life assessed by European Quality of Life 5 Dimensions Questionnaire (EQ-5D)

  10. Symptom control assessed by patient-reported quality of life (QoL): EORTC QLQ-C30 [ Time Frame: 24 months ]
    patient-reported quality of life assessed by Questionnaire of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

  11. Symptom control assessed by patient-reported quality of life (QoL): EORTC QLQ-LC29 [ Time Frame: 24 months ]
    EORTC QLQ-LC29



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed non-squamous NSCLC harboring EGFR mutation positive but T790M mutation negative by local testing
  • Unresectable stage UICC ≥ IIIb or metastatic stage UICC IV disease
  • TKI naïve for metastatic NSCLC, neoadjuvant or adjuvant chemotherapy allowed
  • At least one evaluable lesion according to RECIST v1.1
  • Age ≥ 18 years
  • ECOG performance status 0 - 2
  • Adequate organ function, defined as all of the following:

    1. Absolute neutrophil count (ANC) ≥ 1500/mm3. (ANC > 1000/mm3 may be considered in special circumstances such as benign cyclical neutropenia as judged by the investigator and in discussion with the coordinating investigator)
    2. Platelet count ≥ 75,000/mm3
    3. Estimated glomerular filtration rate (eGFR) > 45 ml/min/1.73 m2 according to the Cockcroft-Gault formula d. If history of cardiac comorbidity: Left ventricular function with resting ejection fraction ≥ 50% or above the institutional lower limit of normal (LLN)

    e. Total Bilirubin ≤ 1.5 times upper limit of normal (ULN), (if related to liver metastases ≤ 3 times ULN). (Patients with Gilbert's syndrome total Bilirubin must be ≤ 4 times institutional upper limit of normal) f. Aspartate amino transferase (AST) or alanine amino transferase (ALT) ≤ 3 times the upper limit of normal (ULN) (if related to liver metastases ≤ 5 times ULN)

  • Recovered from any previous therapy related toxicity to ≤ Grade 1 at before randomization (except for stable sensory neuropathy ≤ Grade 2 and alopecia)
  • Written informed consen

Exclusion Criteria:

  • Any investigational drug within 30 days or hormonal anticancer treatment within 2 weeks prior to randomization (continued use of anti-androgens and/or gonadorelin analogues for treatment of prostate cancer permitted)
  • T790M mutation positive tumors (by local testing)
  • Radiotherapy within 2 weeks prior to randomization, except as follows:

    1. Palliative radiation to target organs other than chest may be allowed up to 1 week prior to randomization
    2. Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with coordinating investigator prior to enrolling
  • Major surgery within 2 weeks before starting study treatment or scheduled for surgery during the projected course of the study
  • Known hypersensitivity to afatinib or osimertinib or the excipients of any of the trial drugs
  • History or presence of clinically relevant cardiovascular abnormalities such as

    1. uncontrolled hypertension
    2. congestive heart failure NYHA classification of ≥ 3
    3. unstable angina or poorly controlled arrhythmia as determined by the investigator
    4. Myocardial infarction within 6 months prior to randomization
    5. Clinically important abnormalities in rhythm and conduction as measured by resting electrocardiogram (ECG) (e.g. QTc interval greater than 470 ms) or QTc interval prolongation with signs/symptoms of serious arrhythmia
    6. Congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or intake of medicinal products that are known to prolong the QTc interval
  • Patients with a past or present medical history of

    1. Interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD
    2. Any history of or concomitant condition that, in the opinion of the Investigator, would compromise the patient's ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug
    3. Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. Crohn's disease, ulcerative colitis, chronic diarrhoea, malabsorption)
    4. Known active hepatitis B infection (defined as presence of HepB sAg and/ or Hep B DNA), active hepatitis C infection (defined as presence of Hep C RNA) and/or known HIV carrier
    5. Previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 5 years and is considered to be cured
  • Pregnancy and contraception:

    1. Women who are pregnant, nursing, or who plan to become pregnant while in the trial
    2. Women of child-bearing potential (WOCBP) and men who are able to father a child, unwilling to be abstinent or use highly effective methods of birth control that result in a low failure rate of less than 1% per year when used consistently and correctly beginning at informed consent, for the duration of study participation and for at least 2 months for females and 4 months for males after last dose
  • Requiring treatment with any of the prohibited concomitant medications protein Inhibitors/Inductors CYP3A4/5 Inhibitors/Inductors that cannot be stopped for the duration of trial participation or concomitant St. John's Wort
  • Uncontrolled brain metastases (Patients with brain or subdural metastases are not eligible, unless they have completed local therapy (≤ 2 weeks apart from last radiotherapy or radiosurgery) and have discontinued the use of corticosteroids, anticonvulsants or have been on stable dose of corticosteroids (i.e. Dexamethasone ≤ 8 mg) for at least 4 weeks before starting study treatment. Any symptoms attributed to brain metastases must be stable for at least 4 weeks before starting study treatment) or Leptomeningeal carcinomatosis 11. Other contraindications to study treatment (Investigators opinion) or legal incapacity or limited legal capacity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04413201


Contacts
Layout table for location contacts
Contact: Anne Ehrlich, Dr med +49 6131 17 ext 9945 ehrich@izks-mainz.de
Contact: Jana Topsch, Dr rer nat +49 6131 17 ext 9932 topsch@izks-mainz.de

Locations
Layout table for location information
Germany
Evangelische Lungenklinik Berlin Recruiting
Berlin, Germany, 13125
Contact: Christian Grohe, Professor         
Contact: Sylke Kurz, PhD         
Studiengesellschaft Hämato-Onkologie Hamburg Recruiting
Hamburg, Germany, 20251
Contact: Eckart Laack, Professor         
Contact: Birte Andritzky, PhD         
Evangelisches Krankenhaus Hamm Recruiting
Hamm, Germany, 59063
Contact: Thomas Wehler, Prof Dr med    +49 2381 589 ext 1864    thomas.wehler@valeo-kliniken.de   
Klinik Löwenstein gGmbH Recruiting
Löwenstein, Germany, 74245
Contact: Jürgen Fischer, PhD         
Contact: Nenad Bogdan, PhD         
Universitätsklinikum Regensburg Recruiting
Regensburg, Germany, 93053
Contact: Christian Schulz, Professor         
Contact: Maximilian V Malfertheiner, PhD         
Sponsors and Collaborators
Michael Hopp
Boehringer Ingelheim
Investigators
Layout table for investigator information
Principal Investigator: Thomas Wehler, Prof Dr med Evangelisches Krankenhaus Hamm
Layout table for additonal information
Responsible Party: Michael Hopp, Head of Interdisciplinary Center for Clinical Studies (IZKS), Johannes Gutenberg University Mainz
ClinicalTrials.gov Identifier: NCT04413201    
Other Study ID Numbers: AFAMOSI
2019-002197-31 ( EudraCT Number )
First Posted: June 2, 2020    Key Record Dates
Last Update Posted: September 30, 2020
Last Verified: September 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Afatinib
Osimertinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action